FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1480235848> ?p ?o ?g. }

• W1480235848 endingPage "e0133133" @default.
• W1480235848 startingPage "e0133133" @default.
• W1480235848 abstract "Bevacizumab combined with modified FOLFOX6 is a standard regimen for colorectal cancer. The present study was to determine the efficacy and safety of bevacizumab-modified FOLFOX6 regimen in heavily pretreated patients with human epidermal growth factor receptor 2 (HER2/neu)-negative MBC.Bevacizumab, 5 mg/kg every two weeks or 7.5 mg/kg every three weeks, was administered with modified FOLFOX6 (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-FU 400 mg/m2 on day 1, followed by 5-FU 2400 mg/m2 intravenous infusion over 46 hours every 2 weeks) to patients who failed at least 1 chemotherapy regimen in the metastatic setting. The primary objective was progression free survival (PFS). Secondary objectives included objective response rate (ORR), clinical benefit rate (CBR), overall survival (OS), safety, and the change of tumor size and Eastern Cooperative Oncology Group (ECOG) performance status.69 patients were enrolled. The median PFS was 6.8 months (95% CI, 5.0 to 8.5 months), ORR was 50.0% and median OS was 10.5 months (95% CI, 7.9 to 13.1 months). Patients showing objective responses had a 4.2-month median PFS gain and 5.7-month median OS gain compared with those who did not (P < 0.05). Grade 3 or 4 adverse events occurring in more than one patient were neutropenia (53/69, 76.8%), leukopenia (36/69, 52.2%), thrombocytopenia (13/69, 18.8%), anemia (3/69, 4.3%) and hypertension (3/69, 4.3%).Adding bevacizumab to modified FOLFOX6 does have significant anti-tumor activity and good safety profile in heavily pretreated HER2/neu-negative MBC patients. Further trials are required to confirm whether the high ORR can translate into a long-term PFS and even OS benefit.www.clinicaltrials.gov NCT01658033." @default.
• W1480235848 created "2016-06-24" @default.
• W1480235848 creator A5011025030 @default.
• W1480235848 creator A5020146176 @default.
• W1480235848 creator A5040983343 @default.
• W1480235848 creator A5047855118 @default.
• W1480235848 creator A5050538615 @default.
• W1480235848 creator A5054500022 @default.
• W1480235848 creator A5057209439 @default.
• W1480235848 creator A5061817335 @default.
• W1480235848 creator A5062321435 @default.
• W1480235848 creator A5065297872 @default.
• W1480235848 creator A5073681238 @default.
• W1480235848 creator A5075732221 @default.
• W1480235848 creator A5076833306 @default.
• W1480235848 creator A5084307208 @default.
• W1480235848 date "2015-07-17" @default.
• W1480235848 modified "2023-10-16" @default.
• W1480235848 title "Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial" @default.
• W1480235848 cites W1816099873 @default.
• W1480235848 cites W1972362283 @default.
• W1480235848 cites W1979080372 @default.
• W1480235848 cites W1991469761 @default.
• W1480235848 cites W2006297166 @default.
• W1480235848 cites W2007679672 @default.
• W1480235848 cites W2008907131 @default.
• W1480235848 cites W2009930501 @default.
• W1480235848 cites W2012079339 @default.
• W1480235848 cites W2019607817 @default.
• W1480235848 cites W2063980813 @default.
• W1480235848 cites W2064680741 @default.
• W1480235848 cites W2076017354 @default.
• W1480235848 cites W2076668534 @default.
• W1480235848 cites W2079898907 @default.
• W1480235848 cites W2090941518 @default.
• W1480235848 cites W2095704084 @default.
• W1480235848 cites W2095832858 @default.
• W1480235848 cites W2096745115 @default.
• W1480235848 cites W2099919027 @default.
• W1480235848 cites W2103563357 @default.
• W1480235848 cites W2108100419 @default.
• W1480235848 cites W2113818241 @default.
• W1480235848 cites W2114159573 @default.
• W1480235848 cites W2119541084 @default.
• W1480235848 cites W2122074158 @default.
• W1480235848 cites W2122574381 @default.
• W1480235848 cites W2122970222 @default.
• W1480235848 cites W2125447919 @default.
• W1480235848 cites W2126275851 @default.
• W1480235848 cites W2132049943 @default.
• W1480235848 cites W2133140705 @default.
• W1480235848 cites W2136451551 @default.
• W1480235848 cites W2139927762 @default.
• W1480235848 cites W2140103603 @default.
• W1480235848 cites W2143743735 @default.
• W1480235848 cites W2144727586 @default.
• W1480235848 cites W2148415679 @default.
• W1480235848 cites W2148911877 @default.
• W1480235848 cites W2149347983 @default.
• W1480235848 cites W2153982924 @default.
• W1480235848 cites W2161036119 @default.
• W1480235848 cites W2165819904 @default.
• W1480235848 cites W2167138718 @default.
• W1480235848 cites W2167224460 @default.
• W1480235848 cites W2169210177 @default.
• W1480235848 cites W2178225042 @default.
• W1480235848 cites W2275088062 @default.
• W1480235848 cites W2024508311 @default.
• W1480235848 doi "https://doi.org/10.1371/journal.pone.0133133" @default.
• W1480235848 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4506015" @default.
• W1480235848 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26186012" @default.
• W1480235848 hasPublicationYear "2015" @default.
• W1480235848 type Work @default.
• W1480235848 sameAs 1480235848 @default.
• W1480235848 citedByCount "7" @default.
• W1480235848 countsByYear W14802358482017 @default.
• W1480235848 countsByYear W14802358482018 @default.
• W1480235848 countsByYear W14802358482019 @default.
• W1480235848 countsByYear W14802358482022 @default.
• W1480235848 crossrefType "journal-article" @default.
• W1480235848 hasAuthorship W1480235848A5011025030 @default.
• W1480235848 hasAuthorship W1480235848A5020146176 @default.
• W1480235848 hasAuthorship W1480235848A5040983343 @default.
• W1480235848 hasAuthorship W1480235848A5047855118 @default.
• W1480235848 hasAuthorship W1480235848A5050538615 @default.
• W1480235848 hasAuthorship W1480235848A5054500022 @default.
• W1480235848 hasAuthorship W1480235848A5057209439 @default.
• W1480235848 hasAuthorship W1480235848A5061817335 @default.
• W1480235848 hasAuthorship W1480235848A5062321435 @default.
• W1480235848 hasAuthorship W1480235848A5065297872 @default.
• W1480235848 hasAuthorship W1480235848A5073681238 @default.
• W1480235848 hasAuthorship W1480235848A5075732221 @default.
• W1480235848 hasAuthorship W1480235848A5076833306 @default.
• W1480235848 hasAuthorship W1480235848A5084307208 @default.
• W1480235848 hasBestOaLocation W14802358481 @default.
• W1480235848 hasConcept C121608353 @default.
• W1480235848 hasConcept C126322002 @default.
• W1480235848 hasConcept C141071460 @default.

• next